Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
J Neuroimmunol ; 373: 577994, 2022 Dec 15.
Article in English | MEDLINE | ID: covidwho-2086467

ABSTRACT

Neuromyelitis optica spectrum disorder (NMOSD) is rarely reported following Coronavirus disease 2019 (COVID-19) vaccination. We identified 16 cases of new onset NMOSD with positive aquaporin-4 IgG (AQP4-IgG) following COVID-19 vaccination. Transverse myelitis was the most common clinical presentation (75%). Most patients received high dose steroids for acute treatment and maintenance therapy was started in 12 patients (75%). Twelve patients (75%) had improvement of their symptoms at the time of discharge or follow-up. The included cases share similar epidemiology and natural course to non-vaccine related cases. Clinicians should be aware of possible post-vaccination NMOSD to help with earlier diagnosis and treatment.


Subject(s)
COVID-19 , Neuromyelitis Optica , Humans , Neuromyelitis Optica/drug therapy , Neuromyelitis Optica/etiology , Neuromyelitis Optica/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines/adverse effects , Autoantibodies , Aquaporin 4 , Vaccination/adverse effects , Immunoglobulin G
SELECTION OF CITATIONS
SEARCH DETAIL